Became the first drug evaluation GLP Institute in South China to pass FDA GLP inspection and the first in China to pass FDA “Unannounced Inspections”

Received approval for the initiative of 2025 National Major Project on Infectious Disease Prevention and Control

Received an “Excellent” rating in the evaluation of Provincial Enterprise Technology Center in Guangdong Province

Established the Craftsman Academy with key support from the Guangzhou Federation of Trade Unions

Obtained the OECD GLP veterinary drug expansion certification

Renewed the AAALAC International Full Accreditation

Awarded a “Five-Star” rating for laboratory animal institution welfare and ethics from the Chinese Association for Laboratory Animal Sciences.

Obtained national CMA qualification for medical devices

Recognized as the Guangdong Engineering Research Center for Innovative Drug Evaluation and Research

Received the First Prize of Guangdong Provincial Science and Technology Progress Award

Obtained the OECD GLP Certification

Designated as one of the first batch of pilot enterprises for the reform of engineering master’s and doctoral cultivation in Guangdong Province

Recognized as a Provincial-level Single Champion Manufacturing Enterprise in Guangdong Province

Recognized as the Guangdong Provincial Service-oriented Manufacturing Demonstration Platform

Renewed as a National Key Specialized, Sophisticated, Distinctive and Innovative "Little Giant" Enterprise

Expert from Lewwin Pharm selected for the National “Ten Thousand Talents Plan” as a Technological Leading Leader.

Expert from Lewwin Pharm elected as a Chairperson of a National-level Academic Society

Obtained the CNAS Laboratory Accreditation

Obtained the CMA expansion certification

Broke ground for the Internationally Advanced Public Service Platform (Center) for Key Technologies in Innovative Drug Evaluation and Development and Biomedical Industrial Park of Lewwin Pharm

Established the GLP Center of State Key Laboratory of Ophthalmology

Established the Innovation Center for Basic Research in Inflammation and Immune-Related Diseases, Ministry of Education

Obtained the CNAS GLP certification for medical device evaluation and chemical safety testing.

Obtained the CNCA GLP Certification

‍Obtained the NMPA full 10-item drug GLP certification (The first private institute and the first in South China)

Renewed the AAALAC International Full Accreditation

Selected for the National Major Talent Engineering Program

Expert from Lewwin Pharm named as a Leading Talent in Technological Entrepreneurship under the “Guangdong Special Support Program”

Partnered with the team of Academician Xinzi Chen to establish the Innovative Drug Research Center

Granted the Provincial Key Area R&D Program and National Ministry of Science and Technology Emergency R&D Project

Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research rated as a “Good Laboratory”

Recognized as a National Key Specialized, Sophisticated, Distinctive and Innovative “Little Giant” Enterprise (currently the only one in China's GLP Sector)

Established the Ophthalmic Drug Non-Clinical Evaluation and Research Center of the State Key Laboratory of Ophthalmology

The newly expanded facilities passed GLP inspection

Renewed as a New-type R&D Institute in Guangdong Province (Continued)

Established the postdoctoral research station with independent enrollment authority — Guangzhou Bay Area Institute of Biomedicine

Approved as a Guangzhou Postdoctoral Innovation Practice Base

Non-clinical data accepted by the US FDA

Passed the SARS-CoV-2 Pseudovirus Proficiency Testing by the National Institutes for Food and Drug Control

Participated in National Key R&D Program/ National Major Scientific and Technological Special Project for “Significant New Drugs Development”/Guangdong Provincial Key Area R&D Program

Established the Guangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs

Recognized as a Guangdong Provincial Specialized, Sophisticated, Distinctive and Innovative Small and Medium-sized Enterprise

Initiated the project of the Internationally Advanced Public Service Platform (Center) for Integrated Non-Clinical Drug Evaluation in South China

Renewed NMPA Full 9-item GLP Certification

Renewed AAALAC International Full Accreditation

Established the TCM Non-Clinical Evaluation Branch of National Engineering Research Center for Modernization of Traditional Chinese Medicine

Renewed as a National High-Tech Enterprise

Established the National-Local Joint Engineering Research Center for Ultrafine Granular Powder of Chinese Materia Medica

Led the “New Drug Development” Key Project of the Provincial Key Area R&D Program

Accredited as the Service Provider of Guangdong Provincial Science and Technology Innovation Voucher

Recognized as the Guangdong Natural Foundation Affiliated Institution

Passed the Acceptance Inspection for the “Public Service Platform (Center) for Key Technologies in Non-Clinical Drug Evaluation in South China, Compliant with International Standards”, with its project data recognized by the U.S. FDA.

Named an “Excellent Enterprise” at the 7th China Innovation & Entrepreneurship Competition National Finals (Biomedicine Sector)

Designated as the Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research

Established the Guangdong Engineering Technology Research Center of Ophthalmic Drug R&D and Evaluation

Passed the acceptance inspection for the Guangdong Engineering Research Center for Innovative Drug Evaluation and Research

Established the Guangdong Provincial Engineering Laboratory for Ultrafine Granular Powder of Chinese Materia Medica

Initiated the project of Public Service Platform (Center) for Key Technologies in Non-Clinical Drug Evaluation in South China, Compliant with International Standards

Accredited as a New-type R&D Institute in Guangdong Province

Established the Guangdong Engineering Research Center for Innovative Drug Evaluation and Research

Selected for the National Major Talent Engineering Program

Granted the first Class 1 Traditional Chinese Medicine clinical trial approval in Guangdong Province in the past five years for Forsythin and Forsythin Capsules

Participated in the National Major Scientific and Technological Special Project for “Significant New Drugs Development”

Recognized as the Guangzhou Scientific and Technological Innovation Service Institute

Appointed as the Vice-Chairman Unit of Guangzhou Bio-industry Alliance

Obtained the CFDA Full 9-item GLP Certification

Received the AAALAC International Full Accreditation

Recognized as a National High-Tech Enterprise

Designated as the Guangzhou Enterprise Research and Development Institute